Risk–benefit profiles associated with receiving Moderna COVID-19 (mRNA-1273) vaccine as an additional pre-booster dose in immune-mediated dermatologic disease patients with low SARS-CoV-2-specific immunity following the primary series: A prospective cohort study

Seree-aphinan C.Suchonwanit P.Rattanakaemakorn P.Pomsoong C.Ratanapokasatit Y.Setthaudom C.Suangtamai T.Chanprapaph K.Mahidol University2023-05-192023-05-192023-05-01Journal of the European Academy of Dermatology and Venereology Vol.37 No.5 (2023) , e572-e57509269959https://repository.li.mahidol.ac.th/handle/20.500.14594/82060MedicineRisk–benefit profiles associated with receiving Moderna COVID-19 (mRNA-1273) vaccine as an additional pre-booster dose in immune-mediated dermatologic disease patients with low SARS-CoV-2-specific immunity following the primary series: A prospective cohort studyLetterSCOPUS10.1111/jdv.188902-s2.0-851473892451468308336662625